Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...

Weight loss leader Novo Nordisk has had a poor performance at the ... So first of all, it's important to call out we have no new data. And therefore, our confidence remains to be the same.

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for ...

Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,000.00. The company’s shares closed ...

Novo Nordisk has reported the second phase 3 trial ... dosing with CagriSema and a longer period of follow-up, but there's no doubt that the even poorer performance in REDEFINE 2 has further ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Then again, for the time being at least, Eli Lilly is running away with the GLP-1 market and leaving Novo Nordisk, Viking Therapeutics, and even Hims & Hers in the dust. Rich Smith has no position ...

At the same time, American depository receipts of rival Novo Nordisk plunged nearly 8% yesterday, as investors view Lilly to be even more competitive with the new orforglipron data. (Lilly is up ...

This all suggests that orforglipron is useful for both treating diabetes and weight loss -- and with no needles required. Image source: Getty Images. Lilly notes that the ACHIEVE-1 study was only ...